Treace Medical Concepts (TMCI) Cost of Revenue (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Cost of Revenue for 7 consecutive years, with $9.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 1.39% year-over-year to $9.8 million; the trailing twelve-month figure through Jun 2026 stood at $42.2 million (down 0.73% YoY), and the FY2025 full-year result was $42.9 million, up 4.49% from the prior year.
• Cost of Revenue held at $9.8 million in Q2 2026 per TMCI's latest filing, from $9.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.2 million in Q4 2024 and bottomed at $5.1 million in Q1 2022.
• Historically, Cost of Revenue has averaged $9.1 million across 5 years, with a median of $9.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 68.02% in 2022, then decreased 8.41% in 2025.
• Over 5 years, Cost of Revenue stood at $9.0 million in 2022, then climbed by 27.14% to $11.5 million in 2023, then increased by 15.36% to $13.2 million in 2024, then retreated by 8.41% to $12.1 million in 2025, then slipped by 19.38% to $9.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $9.8 million, $9.8 million, and $12.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.